Yet another nano-biohybrid platform that facilitates intranasal administration of the recombinant CCL21 gene for prophylactic immunotherapy has been proposed by Kar et al. The researchers have developed EGF-appended CCL21 vault nanocapsules from Chalmydial membrane protein that can target the tumor cells overexpressing EGFR receptor and elicit an immune response through the phosphorylation of Tyr1173. This evidence concerns the gene CCL21 and neoplasm.